cancer-2018-posters-abstracts

Page 55

allied

academies

Journal of Medical Oncology and Therapeutics | Volume: 3

July 23-25, 2018 | Moscow, Russia

World Cancer Congress

Clinico-economic analysis of PD-1 inhibitor and iBRAF+iMEK combination for treating Metastatic

Melanoma with BRAF V600 mutation

Alexey Cheberda

Center for Pharmacoeconomics Research, Russia

kin melanoma is an important, severe condition and one

of the most aggressive oncological diseases, characterized

by high lethality. Relatively high costs of novel innovative

treatments for this condition necessitate analysis of clinico-

economical properties of such treatments in Russian

healthcare setting. The pharmacoeconomic analysis included

cost-effectiveness analysis and budget impact analysis

performed using a model constructed based on a network

meta-analysis of fist-line treatments of melanoma with BRAF

mutation including target therapy and immunotherapy. The

alternatives compared were PD-1 inhibitor pembrolizumab

compared to nivolumab and BRAF inhibitor combined

with MEK inhibitor. Model assessed total survival, average

progression-free survival and direct costs. Obtained results

indicate that year of pembrolizumab treatment was 29%

less expensive than dabrafenib+trametinib combination,

and 60% less expensive than vemurafenib+cobimetinib,

while also 1,7% less expensive than nivolumab treatment.

Cost-effectiveness ration for pembrolizumab was the

lowest of all alternatives compared, indicating highest

cost-effectiveness. Budget impact analysis has shown that

expansion of pembrolizumab use to 50% (at the expense

of other alternatives) would result in budgetary savings

totalling 1 507,5 million rubles accounted for Russian patient

population size.

Use of pembrolizumab as first-line treatment in patients

with BRAF V600 positive melanoma is thus associated with

highest cost-effectiveness and budgetary savings and is

pharmacoeconomically expedient.